New drug duo targets advanced skin cancer in promising trial
NCT ID NCT07394244
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs together—pucotenlimab and becotatug vedotin—for people with advanced cutaneous squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the combination shrinks tumors better than current treatments. About 38 participants will receive the drugs every 3 weeks for up to 2 years, with regular scans to check progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cencer Center, Shanghai, Shanghai
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- Blood clot marker may predict immunotherapy success in advanced skin cancer
- New drug aims to fight skin cancer in transplant patients
- Could a 2-Week radiation course replace longer treatment for skin cancer?
- French study tracks Real-World skin cancer care for 1500 patients
- New drug KUP-101A enters first human tests for advanced skin cancers